Superworth

Curis price to sales ratio CRIS

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
0.2×
10-year median
6.3×
Against its 10-year history
0th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.2× to 128×
Peer median
34.9×

Curis' price to sales ratio is 0.2× as of Oct 23, 2026.

That is below its ten-year median of 6.3×, lower than on 100% of days in the last ten years.

Over that time it ranged from 0.2× in Oct 2026 to 128× in May 2021.

The median for 10 biotech stocks of a similar size is 34.9×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.2×0.2×3.1×
20251.2×0.9×3.2×
20242.7×2.5×9.9×
20237.4×2.3×9.0×
20225.1×4.6×31.7×
202141.4×39.0×128×
202043.4×2.4×43.4×
20195.4×2.7×8.6×
20182.3×2.3×13.9×
201712.8×12.8×61.0×
201659.6×23.4×65.3×
201548.0×12.6×49.4×
201411.8×7.1×18.7×
201315.9×7.6×44.4×
20129.3×8.3×17.1×

Against its peers

Companies in Biotechnology nearest Curis' size, closest first, today.

CompanyPrice to sales ratio
CRISCuris0.2×
SLXNSilexion Therapeuticsn/m
CLDICalidi Biotherapeuticsn/m
VIVSVivoSim Labs, INC.19.7×
PMCBPharmaCyte Biotechn/a
LIMNLiminatus Pharman/m
AIMAIM ImmunoTech50.1×
CELZCreative Medical Technologyn/m
SNTISenti Biosciencesn/m
INABIN8BIOn/m
INTSIntensity Therapeuticsn/m
Peer median34.9×

Where Curis ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Curis

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.